Oculis Holding AG (NASDAQ:OCS – Get Free Report)’s share price was down 4.3% during trading on Monday . The company traded as low as $15.34 and last traded at $15.35. Approximately 10,193 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 36,993 shares. The stock had previously closed at $16.04.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Oculis in a report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $29.20.
Get Our Latest Stock Report on Oculis
Oculis Stock Up 0.5 %
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Featured Stories
- Five stocks we like better than Oculis
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 2 Off-Price Retail Titans: Which Stock Has More Upside in 2025?
- Transportation Stocks Investing
- Kohl’s Faces Holiday Hurdles, But Key Factors Offer Hope
- What Are Dividend Challengers?
- Dogs of the Dow: 3 Stocks Poised for a 2025 Rebound
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.